Three biotechnology companies sued Columbia University on Tuesday, alleging that the school has illegally extended the life of a lucrative patent for gene-splicing technology. Biogen Inc., Genzyme Corp., and Abbott Laboratories filed the lawsuit in U.S. District Court in Boston, claiming they have collectively paid tens of millions of dollars in royalties to Columbia for using the technology, and should not have to pay more.
July 17, 2003 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Presented by BigVoodoo
This conference aims to help insurers and litigators better manage complex claims and litigation.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
Zeisler & Zeisler, P.C., a highly-regarded corporate restructuring, bankruptcy and commercial litigation boutique, seeks an attorney to ...
General Counsel Posting Number: 1925 Closing Date: Location: Oakland, CA (Hybrid) The Public Health Institute (PHI) is an in...
We are seeking an associate to join our Bankruptcy & Creditors Rights practice in either Hartford or Stamford. Candidates should have a...